{"disease":{"id":"pharmacokinetics-of-mirabegron","name":"pharmacokinetics of mirabegron"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00940121","title":"Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT02211846","title":"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT04641975","title":"A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":26,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT04501640","title":"A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Astellas Pharma China, Inc.","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}